Pharmaceutical company intelligence

Highnoon Laboratories Ltd

Public listed pharmaceutical manufacturer · Lahore · Pakistan

Publicly listed Lahore pharmaceutical manufacturer with a broad therapeutic portfolio, research and development operations and national distribution.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.

Official website ↗ Official contact ↗

Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details

Latest regulatory-source observation22 Sep 2026Newest linked source record observed by MedInfoBase

Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio

Latest effective price date27 Jul 2026Newest effective date among published current price records

Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Location intelligence

Company location

Google Maps

Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗

Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view

Rx174public portfolio records represented

REG116unique registrations represented

IDX9indexed MedInfoBase presentations

SRC0additional source-observed presentations

R+0registry-only registrations

VER0registry-verified exact registrations

PKR151current validated price records

G50generic molecules in indexed catalogue

DF8dosage-form groups

TA10therapeutic areas

How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage87%

public portfolio presentations with a validated current price

Official-source coverage100%

products linked back to a source record

Unit-price parse coverage81%

priced packs safely normalized per unit

Comparable-market coverage73%

products with at least one like-for-like comparator

Therapeutic classification100%

products assigned to a broad therapeutic area

Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives51 products · 31%

Respiratory & allergy36 products · 22%

Hematology & thrombosis23 products · 14%

Cardiovascular14 products · 8%

Endocrine & metabolic13 products · 8%

Oncology & immunology12 products · 7%

CNS & mental health7 products · 4%

Gastrointestinal & hepatology7 products · 4%

Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Inhaled controller therapy25 products · 15%

Antimalarials18 products · 11%

Antidiabetic medicines13 products · 8%

Anticoagulants12 products · 7%

Antivirals12 products · 7%

Antineoplastic medicines10 products · 6%

Calcium-channel blockers9 products · 5%

Fluoroquinolone antibacterials8 products · 5%

Formulation footprint

Dosage forms

Tablet92 products

Inhalation35 products

Injection26 products

Suspension5 products

Capsule4 products

Solution2 products

Drops1 products

Syrup1 products

How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales

#1 CombivairBudesonide + Formoterol 12presentations 100 mcg + 6 mcg, 200 mcg + 6 mcg, 400 mcg + 6 mcg, 6 mcg + 100 mcg · Inhalation #2 AmonateArtesunate + Amodiaquine 10presentations 100 mg + 270 mg, 25 mg + 67.5 mg, 50 mg + 135 mg · Tablet #3 RivaroRivaroxaban 9presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #4 Misar-AMTelmisartan + Amlodipine 8presentations 40 mg + 10 mg, 40 mg + 5 mg, 80 mg + 10 mg, 80 mg + 5 mg · Tablet #5 EmessonOndansetron 7presentations 4 mg, 4 mg/5 mL, 8 mg · Injection, Tablet, Solution #6 LoprinAcetylsalicylic acid (Aspirin) 6presentations 150 mg, 300 mg, 75 mg · Tablet

Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis

Below market median3025% of comparable products

Near market median48within ±5% of median

Above market median4436% of comparable products

Lowest-price equivalents17ties included

Company median price position +1.1% relative to the median unit price of like-for-like equivalent products.

Most competitively positioned examplesProducts with at least 3 market comparators

Zolebid DS 800 mg + 160 mgSulfamethoxazole + Trimethoprim · Tablet · 100 PKR 4.29/tablet-53.6% vs market median Budevair 400 mcgBudesonide · Inhalation capsule · 30 PKR 12.09/capsule-46.4% vs market median Lexopine 200 mgCarbamazepine · Tablet · 50 PKR 5.81/tablet-46.3% vs market median Amonate 100 mg + 270 mgArtesunate + Amodiaquine · Tablet · 20's PKR 12.99/tablet-32.7% vs market median Amonate 100 mg + 270 mgArtesunate + Amodiaquine · Tablet · 10's PKR 13.31/tablet-31.1% vs market median

How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Getz Pharma (Pvt) Limited308 products · 63 generics 27shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 27shared generics Werrick Pharmaceuticals249 products · 82 generics 27shared generics Macter International Limited256 products · 93 generics 26shared generics Wilson's Pharmaceuticals172 products · 57 generics 25shared generics Atco Laboratories Limited278 products · 94 generics 24shared generics

Regulatory & price activity

Observed database signals

Indexed registration numbers111Distinct registrations among indexed, published, presentation-validated products only

Verified price observations167

Products with a verified price166

Products with multiple price observations1

Source records with multiple versions155

Latest portfolio source check22 Sep 2026

Latest effective price date27 Jul 2026

Latest source observation22 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

116 unique registration(s) · 9 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Drug classCalcium-channel blockers Clear intelligence filters

Brand	Generic	Strength	Form	Pack	Registration	Source-listed price	Unit price	Price position
Misar-AM	Telmisartan + Amlodipine	40 mg + 5 mg	Tablet	20	067815	PKR 983.09	PKR 49.15/tablet	Near median
Misar-AM	Telmisartan + Amlodipine	40 mg + 5 mg	Tablet	14	067815	PKR 745.96	PKR 53.28/tablet	Near median
Misar-AM	Telmisartan + Amlodipine	80 mg + 5 mg	Tablet	20	069151	PKR 1,635.63	PKR 81.78/tablet	20% above median
Misar-AM	Telmisartan + Amlodipine	80 mg + 10 mg	Tablet	10	069151	PKR 886.50	PKR 88.65/tablet	Near median
Misar-AM	Telmisartan + Amlodipine	40 mg + 10 mg	Tablet	20	080482	PKR 1,082.83	PKR 54.14/tablet	Near median
Misar-AM	Telmisartan + Amlodipine	40 mg + 10 mg	Tablet	14	080482	PKR 821.64	PKR 58.69/tablet	9% above median
Misar-AM	Telmisartan + Amlodipine	80 mg + 5 mg	Tablet	20	080483	PKR 1,510.26	PKR 75.51/tablet	11% above median
Misar-AM	Telmisartan + Amlodipine	80 mg + 5 mg	Tablet	14	080483	PKR 1,145.97	PKR 81.86/tablet	20% above median
Misar-AM 80/10	Telmisartan + Amlodipine	80 mg + 10 mg	Tablet	10	069151	PKR 886.50	PKR 88.65/tablet	Near median

MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record

MedInfoBase. (2026). Highnoon Laboratories Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/highnoon-laboratories-ltd/

Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.

Highnoon Laboratories Ltd

What is sourced, and how recent is it?

Company profile

Company location

Portfolio at a glance

How complete is this profile?

Downloadable company intelligence charts

Therapeutic Portfolio Mix

Dosage Form Portfolio

Equivalent Price Position

Closest Portfolio Competitors

Therapeutic areas

Drug classes

Dosage forms

Deepest brand families

Unit-price positioning vs equivalent products

Portfolio overlap

Observed database signals

Medicine portfolio

Cite this record